The United Kingdom and the United States have concluded a landmark bilateral deal that will ensure no levies on British drug products going into the US market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to boost spending on pharmaceuticals through the NHS. This pledge secures that import taxes on these crucial products will be held at zero for a duration of three years.
This development comes after recent warnings to significantly raise import taxes on branded pharmaceutical products, with potential rates mentioned reaching one hundred percent.
"This arrangement between the UK strengthens the global environment for new treatments and introduces long-overdue balance to American-British pharmaceutical trade," an announcement noted.
Trade Significance
Pharmaceuticals constitute one of the UK's biggest exports to the America, which is clearly the primary buyer for major UK drugmakers.
Statistics show that in the 12 months prior to last September, the UK shipped medicines totaling over eleven billion pounds to the US. This amount made up a significant portion of British export trade in that timeframe.
"This deal safeguards work, stimulates investment and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Key British Pledges
The agreement involves several specific changes from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to increase overall health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to stay within budget will be capped at 15%. Last year, refunds were more than twenty percent.
Recent Tensions
The pact comes amid a ongoing dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
This friction were intensified by claims that US customers were paying significantly more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar investments have been announced toward American operations.
A senior figure stated that the NHS needed to spend more on drugs, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the last ten years.
